AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|AAPL347.10+3.19 (+0.93%) ▲|ABBV286.39-0.35 (-0.12%) ▼|ABT103.10-1.78 (-1.70%) ▼|ACN235.16-12.07 (-4.88%) ▼|ADBE248.36-10.26 (-3.97%) ▼|AMAT395.93+8.34 (+2.15%) ▲|AMD560.26+28.98 (+5.45%) ▲|AMGN447.95+3.32 (+0.75%) ▲|AMT183.83-4.45 (-2.36%) ▼|AMZN253.10+4.01 (+1.61%) ▲|AVGO342.33+13.16 (+4.00%) ▲|AXP312.91-2.14 (-0.68%) ▼|BA168.18-20.13 (-10.69%) ▼|BAC50.68+0.16 (+0.32%) ▲|BKNG150.14-3.00 (-1.96%) ▼|BLK1,136.05+8.39 (+0.74%) ▲|BMY61.55-0.06 (-0.10%) ▼|BNY147.58+0.40 (+0.27%) ▲|BRK-B542.99-5.57 (-1.02%) ▼|C122.69+1.65 (+1.36%) ▲|CAT713.31+21.18 (+3.06%) ▲|CL92.17-0.93 (-1.00%) ▼|CMCSA21.84-0.21 (-0.95%) ▼|COF203.44+1.09 (+0.54%) ▲|COP147.96-3.41 (-2.25%) ▼|COST992.13-13.03 (-1.30%) ▼|CRM240.89-6.72 (-2.71%) ▼|CSCO111.38+1.14 (+1.03%) ▲|CVS91.13-1.40 (-1.51%) ▼|CVX228.23-3.78 (-1.63%) ▼|DE639.58-1.67 (-0.26%) ▼|DHR232.00-0.97 (-0.42%) ▼|DIS110.23-0.17 (-0.15%) ▼|DUK124.80+0.36 (+0.29%) ▲|EMR166.27+4.57 (+2.83%) ▲|FDX307.10+6.52 (+2.17%) ▲|GD354.89-2.15 (-0.60%) ▼|GE297.66+9.23 (+3.20%) ▲|GEV895.08+40.46 (+4.73%) ▲|GILD159.08+0.39 (+0.25%) ▲|GM80.54+4.23 (+5.54%) ▲|GOOG316.83+2.64 (+0.84%) ▲|GOOGL320.58+3.78 (+1.19%) ▲|GS911.77+18.49 (+2.07%) ▲|HD318.50-0.88 (-0.28%) ▼|HON218.81-0.47 (-0.21%) ▼|IBM250.25-3.19 (-1.26%) ▼|INTC93.74+3.27 (+3.61%) ▲|INTU328.45-11.44 (-3.37%) ▼|ISRG445.88-5.75 (-1.27%) ▼|JNJ268.73+2.43 (+0.91%) ▲|JPM335.79+1.75 (+0.52%) ▲|KO91.18-1.52 (-1.64%) ▼|LIN508.65+1.09 (+0.21%) ▲|LLY1,281.91+2.77 (+0.22%) ▲|LMT622.99-12.21 (-1.92%) ▼|LOW198.18-0.04 (-0.02%) ▼|LRCX240.85+3.35 (+1.41%) ▲|MA609.85-3.65 (-0.59%) ▼|MCD249.47-1.36 (-0.54%) ▼|MDLZ62.35-0.62 (-0.98%) ▼|MDT93.95-0.84 (-0.89%) ▼|META620.19-10.37 (-1.64%) ▼|MMM171.58-1.21 (-0.70%) ▼|MO73.49-0.13 (-0.18%) ▼|MRK141.82+1.21 (+0.86%) ▲|MS186.91+3.42 (+1.86%) ▲|MSFT531.33-1.27 (-0.24%) ▼|MU928.76+25.06 (+2.77%) ▲|NEE82.42+0.38 (+0.46%) ▲|NFLX62.52-1.38 (-2.16%) ▼|NKE37.56-0.35 (-0.92%) ▼|NOW154.78-3.40 (-2.15%) ▼|NVDA217.94+1.94 (+0.90%) ▲|ORCL130.53+4.47 (+3.55%) ▲|PEP133.50-1.96 (-1.45%) ▼|PFE29.80+0.01 (+0.03%) ▲|PG159.23-0.69 (-0.43%) ▼|PLTR198.73-0.11 (-0.06%) ▼|PM202.62+0.75 (+0.37%) ▲|QCOM184.17+4.57 (+2.54%) ▲|RTX194.60-2.88 (-1.46%) ▼|SBUX103.04+0.35 (+0.34%) ▲|SCHW89.30-0.43 (-0.48%) ▼|SO92.65+0.08 (+0.09%) ▲|SPG212.28-0.41 (-0.19%) ▼|T20.94+0.09 (+0.43%) ▲|TMO693.02+8.13 (+1.19%) ▲|TMUS146.83-0.10 (-0.07%) ▼|TSLA407.46+15.84 (+4.04%) ▲|TXN308.91+10.79 (+3.62%) ▲|UBER65.78-0.35 (-0.53%) ▼|UNH410.39-0.31 (-0.08%) ▼|UNP299.88+2.91 (+0.98%) ▲|UPS106.09+5.77 (+5.75%) ▲|USB59.74+0.04 (+0.07%) ▲|V401.86-2.30 (-0.57%) ▼|VZ43.93+0.83 (+1.93%) ▲|WFC82.66+0.01 (+0.01%) ▲|WMT119.32-0.97 (-0.81%) ▼|XOM179.91-4.63 (-2.51%) ▼|
9.7 C
New York
Wednesday, October 28, 2026

Tag: TRI

newsFORsourcecompanycontentinformation1releasesmarket

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

Magellan Jets Unveils Fractional Ownership Program, Powered by Slate Aviation, with Bombardier Challenger 850

QUINCY, Mass. and WEST PALM BEACH, Fla., June 30, 2025 /PRNewswire/ -- Magellan Jets, a leader in private aviation solutions, today announced the launch of...

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- InterShunt Technologies, Inc., a medical device company focused on...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled...

SELECT MEDICAL SIGNS AGREEMENT WITH BALLAD HEALTH TO OPERATE JOINT VENTURE CRITICAL ILLNESS RECOVERY HOSPITAL

MECHANICSBURG, Pa., June 27, 2025 /PRNewswire/ -- Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate...

GC Biopharma USA Highlights Innovative Manufacturing Approach to IVIG Safety at 2025 CIS Annual Meeting

Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

Cellarity Initiates Phase 1 Clinical Study of CLY-124, a First-in-Class Globin-Switching Oral Medicine for the Treatment of Sickle Cell Disease

Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal hemoglobin with no cytotoxicity Novel Globin-Switching mechanism derived from...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers